The European society for medical oncology (ESMO) announced their fellowship award recipients at the ESMO Congress took place in October in Milan. ESMO awarded seven translational fellowships and two clinical research grants. One of the recipients which becomes fellow, Dr. Guilia Pasello translational concentrate their research on the "discovery of novel molecular targets and biological agents for malignant pleural mesothelioma chemotherapy."
Mesothelioma, a rare form of cancer primarily through exposure to airborne asbestos fibres, commonly affecting the lining of the lungs, causing very aggressive and resistant against many standard cancer treatments. There are currently no known cure for mesothelioma. Through continuous research, hope doctors and scientists to explore new approaches to treating disease procedures to identify the disease at an early stage and found to develop a cure.
Translational research is often called aspect of scientific discovery of the "Bank to bed". This is where the findings are translated into practical applications. Scientists begin the process to "the Bank" basic research such as offer disease at the molecular level and then the tools to study, to clinicians, innovation at the clinical level or at the patient's bed. ESMO translationale research grants to provide training in translational research in a European Center with an international reputation in the field. The Translational fellowship program lasts up to 2 years.
Pasello is a researcher in the Department of medical oncology Istituto Oncologico Veneto, where your research in lung cancer and mesothelioma focused clinical trials currently. It was by a doctor in 2005 and spent her first year of postgraduate training at the Institute for oncological and surgical Sciences, Oncology section at the Istituto Oncologico Veneto IRCSS, Padua.
Pasello is co-author of numerous studies including "molecular targets in malignant pleural mesothelioma treatment," "second and third line treatment for advanced non-small cell lung cancer," and "induction senescence marker after neo adjuvant chemotherapy malignant pleural mesothelioma and link to clinical outcome: an exploratory analysis." One of your studies confirmed the safety and efficacy of AVASTIN as chemotherapy for lung cancer and potentially for mesothelioma.
ESMO is the leading European professional organization promoting specialty of medical oncology and promote a multidisciplinary approach committed to cancer treatment and care. Through their comprehensive fellowship program young oncologists are given the opportunity, "gain valuable research experience and skills and have the opportunity to disseminate information in their home countries."
ESMO Fellowship Award
